Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. - Wikidata - awgldk - TriplyDB

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

http://www.wikidata.org/entity/Q44835152

about

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients Chronic kidney disease mineral and bone disorder in children Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations Pre-treatment considerations in childhood hypertension due to chronic kidney disease Optimizing haemodialysate composition Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?Hyperparathyroidism of Renal Disease Cinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysis Novel spectrophotometric method for determination of cinacalcet hydrochloride in its tablets via derivatization with 1,2-naphthoquinone-4-sulphonate Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis A New Data Analysis System to Quantify Associations between Biochemical Parameters of Chronic Kidney Disease-Mineral Bone Disease Restoration of bone mineralization by cinacalcet is associated with a significant reduction in calcitriol-induced vascular calcification in uremic rats Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis.Surgical management of secondary hyperparathyroidism in chronic kidney disease--a consensus report of the European Society of Endocrine Surgeons.A computerized treatment algorithm trial to optimize mineral metabolism in ESRD.Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism The vascular Ca2+-sensing receptor regulates blood vessel tone and blood pressure End stage renal disease.Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.The effects of discontinuing cinacalcet at the time of kidney transplantation.G protein-coupled receptors in cardiac biology: old and new receptors Physiology and pathophysiology of the calcium-sensing receptor in the kidney Calciphylaxis in chronic renal failure: An approach to risk factors End-stage renal disease Hypertension and hyperparathyroidism are associated with left ventricular hypertrophy in patients on hemodialysis Diagnosis and management of mineral metabolism in CKD.Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.Cinacalcet hydrochloride (Sensipar).Failed Switching off in the MIBI-Parathyroid Scintigraphy in a Dialyzed Patient with Secondary Hyperparathyroidism Responsive to Cinacalcet Therapy.A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2alpha-mediated Rho/ROCK signaling pathway Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects Targets for parathyroid hormone in secondary hyperparathyroidism: is a "one-size-fits-all" approach appropriate? A prospective incident cohort study Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.The calcium-sensing receptor and related diseases.

P2860

Q24187385-35F2F0D3-3B70-4578-8A9C-71E9E5F8ACAD Q24244091-F840ACA0-9BE6-4CFC-8BD3-B7D406617071 Q24642788-74C75151-08F7-4FFD-9B0F-A82E2E14935C Q24648139-FD83EE1C-3457-4C1A-9A70-04E2D65EDCD9 Q26777613-D0D779A7-064D-4777-9AD6-8537BDFA2AF2 Q26785879-1A653048-B52E-48C0-84B7-DD43915859F2 Q26851487-26840E89-4398-422C-9DCC-996327A0EE87 Q26863412-9278DA85-4301-4089-B1F7-00C6CECF54B7 Q27002431-EABC48AD-0C88-44C9-BAE8-72C8418A04E6 Q28068593-2A947523-96ED-48D6-BE7D-5F8641144AC8 Q28079300-392812B9-C770-47D5-A326-B6881149C3F4 Q28397353-880DE30F-7234-4E4E-A7C6-85AE512D090F Q28484646-EA154CB9-6732-4AAA-8F4B-14F949CF6D67 Q28552810-446B87A5-0B71-4A87-A1C5-2D233320F749 Q28569272-F53BECB1-B589-424C-958F-4225F5970EF3 Q30251450-ACD8F96C-1889-4CC8-A347-A605E64D4F70 Q30316084-FF693FEA-160C-4D96-9185-DB41A3D20473 Q30421529-25389224-8191-4501-99DE-9C6394727BFD Q30544587-31F63696-11D4-48FC-A9D8-0FA2D9A39D6A Q30835393-6A7C2ADA-1CFC-46D6-BAA3-2C04AC20A417 Q33446829-2B236026-0346-451A-9D9B-F383B9FA7C70 Q33571321-B41328F7-B70C-489C-981F-08CAB350E512 Q33597429-BB84F426-4C54-42A0-9389-ADFA0FC498C5 Q33639685-B6A71592-28AB-4D29-B06C-FA51BC518365 Q33727776-62FE08C7-303D-417B-8E00-9881C348E329 Q33809841-E32D7180-7144-4CA8-8B47-1F883CA9E48A Q33850437-62FBE945-B67D-4A24-BA90-3784A6BB98CB Q33873935-0E921E37-F642-4D41-8C10-1F34B2B35F46 Q33898681-1D338F00-7C80-4779-9356-30E25005FB4E Q33917786-A7603E29-1DAC-46ED-9761-3A36B362C031 Q33945152-2EFAB1D3-BA5B-425D-980D-CC2CA21A5AF9 Q34002025-71E6F9CC-044B-4B1F-A599-4A46F9F604D9 Q34055922-DEB79ED8-80FF-4BCB-8E8A-AA489B9CD8B3 Q34140416-5CC54FFA-4CB4-451E-91FD-679BF30CAFEB Q34362759-93F86607-96B1-41BA-B337-D6D63C594E63 Q34366087-C1AD5823-A676-4249-827A-ACBB969CE47F Q34385273-B45F9BDA-9C17-4B50-9359-C37DCA1B804E Q34538433-7357F36A-F0C8-446B-B3DC-67EC0D3A6AD1 Q34556949-1ACD4421-7DBD-40AD-AA12-BC9E89B7CDDF Q34583240-2877148C-DE30-49D2-9C2A-4632F5DE3485

P2860

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

http://www.wikidata.org/entity/Q44835152

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

@en

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

@nl

type

label

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

@en

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

@nl

prefLabel

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

@en

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

@nl

P1433

Q44835152-D75BBD7B-1265-4889-8F3B-04FAF98A711A

P1476

Q44835152-72526934-54F9-4528-8FF3-4D97461A6D83

P2093

Q44835152-06114FA4-A9E7-4F60-9B70-A64D3C9FEC54

Q44835152-12AA9154-4236-4CA4-B34B-4217E10F30DC

Q44835152-20487185-3FE7-4FEC-8E7C-2E522F0202AE

Q44835152-413CD5BD-13D6-4E03-B71D-9783B6ADF4DE

Q44835152-44C114BF-B187-4799-BBE9-C11FACFAB5D7

Q44835152-54FD83AD-6361-4D5F-9D52-15CE9A5845B0

Q44835152-5885E17F-242C-45F2-AA3F-1897E5DA1C55

Q44835152-740FBD97-6FFD-451A-B980-88F43D6F60F4

Q44835152-7CE4BBF7-9F0B-4EE2-9E4E-F0E2A786937D

Q44835152-7E0A59A7-20D1-4855-A724-EF58558623DB

P304

Q44835152-AD82C292-EAE6-4260-9FE4-3868392EBC2A

P31

Q44835152-D7539B5E-B4A1-41D1-B1DE-91B9F49DA2E8

P356

Q44835152-21BF0561-2D5D-4BC9-B4CD-3E5815E709B2

P407

Q44835152-5D01221C-6CD6-4E7F-9B4F-6643FE354098

P433

Q44835152-0C1D80ED-BCED-435C-BDF8-5FB6B991EAF6

P478

Q44835152-4C27E5A7-CFBF-4919-91D7-63B22F94DC61

P577

Q44835152-5287115B-DA30-4484-9EBD-C782B848848E

P698

Q44835152-523024BD-2BDA-4DC4-BED4-1C8E9C2E4A1B

P921

Q44835152-7B896863-D022-46DF-B042-C2F8560F6FEC

P356

P1433

The New England Journal of Medicine

P1476

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

@en

P2093

Albert Fournier

http://www.w3.org/2001/XMLSchema#string

Ali K Abu-Alfa

http://www.w3.org/2001/XMLSchema#string

Angel L M de Francisco

http://www.w3.org/2001/XMLSchema#string

Daniel W Coyne

http://www.w3.org/2001/XMLSchema#string

Francesco Locatelli

http://www.w3.org/2001/XMLSchema#string

Gavril Hercz

http://www.w3.org/2001/XMLSchema#string

Geoffrey A Block

http://www.w3.org/2001/XMLSchema#string

Johann Braun

http://www.w3.org/2001/XMLSchema#string

John Cunningham

http://www.w3.org/2001/XMLSchema#string

Kevin J Martin

http://www.w3.org/2001/XMLSchema#string

P304

1516-1525

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA031633

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

350

http://www.w3.org/2001/XMLSchema#string

P577

2004-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15071126

http://www.w3.org/2001/XMLSchema#string

P921

hyperparathyroidism